MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
Pacific Biosciences of California EBITDA 2011-2026 | PACB
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Pacific Biosciences of California
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -323 M | -298 M | -203 M | -98 M | -90.6 M | -93.8 M | -81.3 M | -67.4 M | -48.5 M | -58.6 M | -71.9 M | -87.7 M | -104 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -48.5 M | -323 M | -125 M |
Quarterly EBITDA Pacific Biosciences of California
| 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | -78.1 M | - | - | - | -88.5 M | - | -67.7 M | -63.4 M | -75.3 M | - | -69.5 M | -34.4 M | -32.1 M | - | -19.3 M | -20.3 M | -31.1 M | -17.9 M | -22.6 M | -20.8 M | -28.3 M | -30.6 M | -19.2 M | -18.1 M | -22.1 M | -20.5 M | -14.9 M | -19.5 M | -20.4 M | -17.9 M | -13.9 M | -16.2 M | -17.7 M | -1.06 M | 5.31 M | -9.51 M | -18.4 M | -17.9 M | -5.1 M | -16 M | -17 M | -17 M | -15.7 M | -17.1 M | -19.1 M | -21.7 M | -17.5 M | -19.2 M | -25.9 M | - | 4.3 M | 2.86 M | -33.5 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 5.31 M | -88.5 M | -25.2 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Diagnostics research industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Trinity Biotech plc
TRIB
|
6.62 M | $ 0.73 | -1.86 % | $ 61.9 M |  Irlanda |
|
Akumin
AKU
|
70.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Aspira Women's Health
AWH
|
-32.5 M | - | -6.19 % | $ 10.5 M |  USA |
 |
Burning Rock Biotech Limited
BNR
|
-749 M | $ 29.0 | -3.07 % | $ 316 M |  China |
 |
Brainsway Ltd.
BWAY
|
-5 M | $ 23.87 | -0.13 % | $ 99.4 M |  Israel |
 |
Accelerate Diagnostics
AXDX
|
-12.3 M | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
-30.3 M | - | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
-90 M | $ 1.14 | -2.16 % | $ 1.45 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-3.26 M | - | - | $ 562 M |  Britain |
 |
Chembio Diagnostics
CEMI
|
-21.1 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-25.8 M | - | - | $ 9.42 M | Israel |
 |
Celcuity
CELC
|
-113 M | $ 104.95 | -1.72 % | $ 4.14 B | USA |
 |
Co-Diagnostics
CODX
|
-41.5 M | - | - | $ 79.8 M | USA |
 |
Danaher Corporation
DHR
|
5.58 B | $ 210.56 | -0.33 % | $ 154 B | USA |
 |
Castle Biosciences
CSTL
|
24.7 M | $ 29.41 | -6.17 % | $ 817 M | USA |
 |
Global Cord Blood Corporation
CO
|
652 M | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
-35.1 M | - | 1.08 % | $ 308 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.84 B | $ 202.21 | -0.11 % | $ 22.4 B | USA |
 |
Genetic Technologies Limited
GENE
|
-6 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | China |
 |
PRA Health Sciences, Inc.
PRAH
|
416 M | - | - | $ 10.7 B | USA |
 |
DexCom
DXCM
|
1.16 B | $ 73.08 | 1.11 % | $ 28.5 B | USA |
 |
DarioHealth Corp.
DRIO
|
-55.7 M | $ 11.75 | 2.8 % | $ 333 M | Israel |
 |
CareDx, Inc
CDNA
|
-189 M | $ 18.83 | -5.23 % | $ 1.01 B | USA |
 |
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | USA |
 |
Enzo Biochem
ENZ
|
-11.1 M | - | -8.98 % | $ 14.8 K | USA |
 |
Illumina
ILMN
|
-479 M | $ 117.53 | -2.06 % | $ 18.7 B | USA |
 |
Fulgent Genetics
FLGT
|
-49 M | $ 23.18 | -0.39 % | $ 701 M | USA |
 |
Exact Sciences Corporation
EXAS
|
-81.4 M | $ 103.45 | 0.15 % | $ 19.5 B | USA |
 |
Lantheus Holdings
LNTH
|
522 M | $ 74.31 | 1.54 % | $ 5.14 B | USA |
 |
Guardant Health
GH
|
-398 M | $ 103.36 | -2.84 % | $ 13 B | USA |
 |
Heska Corporation
HSKA
|
-6.33 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-20.2 M | - | -20.0 % | $ 1.06 M | USA |
 |
ICON Public Limited Company
ICLR
|
1.59 B | $ 99.61 | 1.22 % | $ 8.22 B | Irlanda |
 |
Interpace Biosciences
IDXG
|
8.41 M | $ 1.85 | 2.78 % | $ 8.12 M | USA |
 |
QIAGEN N.V.
QGEN
|
301 M | - | - | $ 10.6 B |  Niderland |
 |
Charles River Laboratories International
CRL
|
428 M | $ 169.68 | 3.11 % | $ 8.41 B | USA |
 |
IDEXX Laboratories
IDXX
|
1.26 B | $ 635.6 | 0.77 % | $ 52.4 B | USA |
 |
IQVIA Holdings
IQV
|
3.33 B | $ 166.19 | -1.87 % | $ 28.6 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
553 M | $ 31.19 | 0.73 % | $ 20 B | Niderland |
|
Biodesix
BDSX
|
-28.7 M | $ 13.26 | 4.0 % | $ 1.72 B | USA |
 |
Quidel Corporation
QDEL
|
1.11 B | $ 22.47 | -4.85 % | $ 947 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
1.73 B | $ 283.38 | 0.32 % | $ 23.8 B | USA |
 |
Biomerica
BMRA
|
-5.05 M | $ 2.17 | -2.25 % | $ 4.98 M | USA |
 |
Bioventus
BVS
|
-24.4 M | $ 8.57 | -0.06 % | $ 537 M | USA |
 |
Medpace Holdings
MEDP
|
562 M | $ 452.99 | 1.47 % | $ 13.1 B | USA |
 |
Motus GI Holdings
MOTS
|
-11.5 M | - | -34.28 % | $ 263 K | Israel |
 |
National Research Corporation
NRC
|
40.2 M | $ 13.65 | 9.64 % | $ 335 M | USA |
 |
Mettler-Toledo International
MTD
|
51.1 M | $ 1 378.44 | 0.14 % | $ 28.4 B |  Schweiz |